Article

Biosyntrx dietary supplement intended to enhance eye health

Biosyntrx this week unveiled ZoOmega-3, a concentrated dietary supplement produced from cold-water fish. ZoOmega-3 is intended to enhance eye and body health and disease prevention.

Chicago-Biosyntrx this week unveiled ZoOmega-3, a concentrated dietary supplement produced from cold-water fish. ZoOmega-3 is intended to enhance eye and body health and disease prevention.

Each capsule of ZoOmega-3 contains 300 mg of ethyl EPA Omega-3 fatty acid, suggested to appropriately inhibit the downstream metabolism of Omega 7 fatty acids, preventing excessive production of pro-inflammatory prostaglandins, which have been suggested in the literature to contribute to silent inflammation when not kept in check.

In addition, each ZoOmega-3 capsule also includes 200 mg of ethyl DHA, another Omega-3 fatty acid, suggested to increase cellular permeability, allowing nutrients such as amino acids, antioxidants, enzymes, vitamins, and minerals to enter cells to address free radical damage and oxidation, as well as to protect mitochondria DNA.

“Excessive amounts of Omega-3 fatty acid can interfere with the body’s ability to mount a life-saving inflammatory response when needed, such as fevers to combat viral or bacterial attack, swelling to protect broken bones, or clotting to stop bleeding,” said Spencer Thornton, MD, president, chief medical officer, and one of the Biosyntrx founders.

Dr. Thornton went on to explain that Biosyntrx recommends one ZoOmega-3 capsule a day for health maintenance and disease prevention, particularly on days that fish is not included in the diet. 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.